David J. Mauro

Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Shirin Khambata‐Ford, Christopher R. Garrett, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 1.1K citations · Full text

Medicine, Genetics, Oncology +17

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Heinz‐Josef Lenz, Eric Van Cutsem, Shirin Khambata‐Ford et al. · Journal of Clinical Oncology · 2006 · 537 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results

Susan L. Boone, Alfred Rademaker, Dachao Liu et al. · Oncology · 2007 · 188 citations

Medicine, Dermatology, Oncology +16

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, Anne S. Tsao et al. · Journal of Clinical Oncology · 2016 · 182 citations

Medicine, Oncology, Pharmacology +17

A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

W. Zhang, Thomas Winder, A. Pohl et al. · Annals of Oncology · 2010 · 134 citations · Full text

Medicine, Genetics, Oncology +15